Ness wins multi-million pact

Ness Technologies said over the weekend it was awarded a multi-million dollar contract by Quintiles Transnational Corp., a provider of pharmaceutical and biotech services.

By JERUSALEM POST STAFF
December 25, 2006 08:04

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

Ness Technologies said over the weekend it was awarded a multi-million dollar contract by Quintiles Transnational Corp., a provider of pharmaceutical and biotech services. Under the three-year pact, which has an optional six-year extension, Ness will establish an Extended Development Center at its Bangalore, India facility, which will provide Quintiles with additional application development, testing and maintenance services in the clinical, laboratory and product commercialization domains.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS